martes, 11 de julio de 2023

Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107501/

No hay comentarios:

Publicar un comentario